Only a fraction of breast cancer (BC) cases can be yet explained by mutations in genes or genomic variants discovered in linkage, genome-wide association and sequencing studies. The known genes entailing medium or high risk for BC are strongly enriched for a function in DNA double strand repair. Thus, aiming at identifying low frequency variants conferring an intermediate risk, we here investigated 17 variants (MAF: 0.01-0.1) in 10 candidate genes involved in DNA repair or cell cycle control. In an exploration cohort of 437 cases and 1189 controls, we show the variant rs3810813 in the SLX4/FANCP gene to be significantly associated with both BC (60 years; OR 5 2.6(1.6-3.9), p 5 1.6E-05) and decreased DNA repair capacity (60 years; beta 5 37.8(17.9-57.8), p 5 5.3E-4). BC association was confirmed in a verification cohort (N 5 2441). Both associations were absent from cases diagnosed >60 years and stronger the earlier the diagnosis. By imputation we show that rs3810813 tags a haplotype with 5 additional variants with the same allele frequency (R 2 > 0.9), and a pattern of association very similar for both phenotypes (cases <60 years, p < 0.001, the Bonferroni threshold derived from unlinked variants in the region). In young cases (60 years) carrying the risk haplotype, micronucleus test results are predictive for BC (AUC > 0.9). Our findings propose a risk variant with high penetrance on the haplotype spanning SLX4/FANCP to be functionally associated to BC predisposition via decreased repair capacity and suggest this variant is carried by a fraction of these haplotypes that is enriched in early onset BC cases.
Only a fraction of breast cancer (BC) cases can be yet explained by mutations in genes or genomic variants discovered in linkage, genome-wide association and sequencing studies. The known genes entailing medium or high risk for BC are strongly enriched for a function in DNA double strand repair. Thus, aiming at identifying low frequency variants conferring an intermediate risk, we here investigated 17 variants (MAF: 0.01-0.1) in 10 candidate genes involved in DNA repair or cell cycle control. In an exploration cohort of 437 cases and 1189 controls, we show the variant rs3810813 in the SLX4/FANCP gene to be significantly associated with both BC (60 years; OR 5 2.6(1.6-3.9), p 5 1.6E-05) and decreased DNA repair capacity (60 years; beta 5 37.8(17.9-57.8), p 5 5.3E-4). BC association was confirmed in a verification cohort (N 5 2441). Both associations were absent from cases diagnosed >60 years and stronger the earlier the diagnosis. By imputation we show that rs3810813 tags a haplotype with 5 additional variants with the same allele frequency (R 2 > 0.9), and a pattern of association very similar for both phenotypes (cases <60 years, p < 0.001, the Bonferroni threshold derived from unlinked variants in the region). In young cases (60 years) carrying the risk haplotype, micronucleus test results are predictive for BC (AUC > 0.9). Our findings propose a risk variant with high penetrance on the haplotype spanning SLX4/FANCP to be functionally associated to BC predisposition via decreased repair capacity and suggest this variant is carried by a fraction of these haplotypes that is enriched in early onset BC cases.
Genes involved in breast cancer susceptibility have been identified by linkage analysis, by sequencing candidate genes in high-risk families, and by genome-wide association studies (GWAS). Linkage analysis and GWAS are not hypothesisdriven; they are, however, not very powerful to detect rare or low-frequency alleles with a moderate effect size. 1, 2 The rather high heritability of breast cancer (BC) (31%) 3 is not yet fully explained by the known breast cancer risk genes and the high number of common susceptibility variants with usually minor effect size. [3] [4] [5] Also, recent studies conducted with massive parallel sequencing technologies did not yield the sought explanations. 6, 7 Low-frequency variants with moderate effect size were suggested to carry the yet unexplained portion of heritability. 8 The simultaneous study of potentially correlated phenotypes has been propagated and used with increasing frequency in recent years 9 in order to improve statistical power and/or obtain insight into functional pathways.
The use of the micronucleus test (MNT) as an isolated test for the assessment of individual BC risk is discussed controversially. The lack of sufficient prediction power was confirmed for individual BC risk by a recent meta-analysis 10 that applied stringent criteria to select high quality studies with micronucleus (MN) frequencies after induction of DNA damage. However, at the same time all these high-quality studies observed elevated mean MN frequencies in breast cancer patient cohorts compared to the mean frequency in control cohorts.
Therefore, we performed an association study for BC utilizing damage-induced MN frequency as a second phenotype. We used a candidate gene approach focusing on lowfrequency alleles with potential functional relevance and excluded genes with a published association to breast cancer. Functional relevance of the candidate genes was considered by restricting the selection of genes to the mechanism of DNA double strand break repair or to G2 checkpoint control. For both cellular functions, tests are available to obtain quantitative measurements (micronucleus test (MNT) and G2 assay, respectively), which can be analyzed as a second phenotype in addition to breast cancer risk.
In this study, we uncovered a low-frequency haplotype spanning SLX4 that confers a considerable risk for early onset breast cancer. SLX4 is a key component of a complex involved in resolving Holliday structures at stalled replication forks and DNA interstrand cross-links. 11, 12 The variant, rs3810813, tagged the specific haplotype with the same MAF and was also independently associated to the second phenotype, reduced capacity to repair DNA double strand breaks. Furthermore, both associations were almost confined to early age of onset (60 years) and the third association, between DNA repair capacity and breast cancer, showed a strong influence of the rs3810813 genotype.
Subjects and Methods

Study cohorts
The detection cohorts comprised 435 breast cancer cases and 1210 controls for genotyping. Out of these, for 135 cases and 299 controls results from the micronucleus test (MNT) could be obtained and used as second phenotype. The verification cohort contained 1425 sporadic breast cancer cases and 1016 controls.
All probands originated from Southern Germany and had given informed consent according to the local IRB.
A detailed description and Supporting Information, Table  S1 of the cohorts can be found in the Supporting Information.
Overall study design
The study was conceived with two phenotypes, breast cancer and DNA repair capacity measured by the MNT, using a candidate gene approach. Ten genes were selected from the DNA double strand repair pathways or the G2/M checkpoint control, which had no known association to breast cancer and carried one missense variant in the low-frequency (0.01 < MAF < 0.10) range. A detailed description of the selection of genes and variants can be found in the Supporting Information. The only variant, rs3810813, associated with both phenotypes (nominal significance, Supporting Information, Table S2 ) was confirmed for early onset breast cancer in the verification cohort. After that we characterized the two associations further by (1) stratification of the patients by age (all, <60 years, <40 years), (2) genotyping of additional SNPs in the region and imputation, and (3) haplotype analysis, testing the mutual association between genotype and each phenotype, as well as between the two phenotypes, and (4) reversed regression of the two phenotypes. Further details of the study and a graphical representation (Supporting Information, Fig. S1 ) can be found in the Supporting Information.
Genotyping
DNA extraction was carried out using standard procedures. Genotyping was performed with predesigned TaqMan variant Genotyping Assays (Applied Biosystems) and TaqMan Genotyping Master Mix (Applied Biosystems) according to the Manufacturer's recommendations in a 384 well microtiter plate format. For TaqMan real-time amplification of all candidate variants in the detection sample, the 7900 Fast Real-Time PCR System (Applied Biosystems) was used and genotypes were called with the Sequence Detection Systems (SDS) 2.4 software (Applied Biosystems). For genotyping of the verification sample as well as for fine mapping, the ViiA7 Real-Time PCR System and Software (Applied Biosystems) were used. Each plate contained at least 1% (4 wells) of nontemplate negative controls and 1% of sample duplicates as internal controls. Cases and controls were mixed on the plates. Failed samples were repeated once.
Imputation and haplotypes
For fine mapping and imputation ( Fig. 1) , we genotyped eight additional markers spanning 150 kb, four in the coding region of SLX4 and two markers each beyond the 5 0 and the 3 0 boarders outside of the coding region. MACH1.0 13 (http:\\www.hapmap.org) and CEU phased haplotypes (HapMap data release
What's new? While genome-wide associations studies (GWASs) have successfully identified susceptibility genes in breast cancer, they have largely missed rare and low-frequency alleles. Here, using a candidate gene approach focused on low-frequency alleles, a new susceptibility locus was discovered for early-onset breast cancer. The haplotype carrying the causal variant spanned the SLX4/FANCP gene and was associated with reduced DNA repair capacity. Because the variant was absent in patients over age 60, the association could not be detected by GWAS without age stratification. The findings suggest that the low-frequency variant is highly penetrant and may carry significant risk for early-onset breast cancer.
#24) 14 were used for imputation in a first round. About 50% (31 variants) of the imputed variants passed quality control in Haploview v4.2 15 (http://www.broadinstitute.org/scientific-community/science/programs/medical-and-population-genetics/haploview) and PLINK v1.07 16 (http://pngu.mgh.harvard.edu/purcell/ plink) and were used to generate the LD plot and define haplotype blocks. As the entire region was in strong LD (D 0 > 0.9) the "solid spine" option of Haploview was used to subdivide the region in LD-blocks. The blocks were separately tested for an association. In a second round, 1000 genomes data 17 were used as reference. The imputed variants were filtered in Haploview4.2 and PLINK v1.07, v1.9 respectively. 14 (http://pngu.mgh.harvard. edu/purcell/plink) 16, 18 for quality control.
Micronucleus assay
The micronucleus assay was carried out by counting micronuclei (MN) in binucleated lymphocytes (cytokinesis-block micronucleus (CBMN) assay) from whole-blood cultures according to standard procedures recommended by the Human micronucleus project 19 and as described recently in detail. 20 An automated imaging system (Metafer 3.1.2, Metasystems, Altlussheim, Germany) was used to score micronuclei in at least 1000 binucleated cells (BNC). The MN counts were recalculated as MN/1000 BNC and normalized, setting the mean of the respective control group to 100 (normalized MN) in order to obtain values comparable among subgroups. The regression coefficient beta in the association between genotype and MN counts denotes the per allele increase of normalized MN over the mean normalized value of the controls (set to one hundred).
Statistical Analyses
The genotype frequencies of all genotyped variants were in HWE (p > 0.1) in controls and cases. The imputed variants were filtered by the standard criteria implemented in PLINK 1.07 and PLINK 1.9, 16, 18 respectively. The analysis of associations between genotype and breast cancer and genotype and MN frequency was carried out using PLINK v. 1.07/1.9 under linear or logistic regression models (additive model with odds ratios reported for the minor allele) where appropriate. The number of "risk alleles" constituted the independent variable, and in the combined analysis of the detection and verification cohort the "cohort" was included as a covariate. As age was suspected to be a modifier of effects it was used for stratification (all cases, age at onset 60 years, age at onset 40 years) in all three associations. The association of DNA repair capacity (MN frequencies) with breast cancer was analyzed by areas (AUC) under receiver operating characteristic (ROC) curves. MN frequency distributions were compared using box-plots and corresponding p values were determined by the Wilcoxon two-sample test. To provide odds ratios in addition, we classified the micronucleus frequencies of all individuals as low or high using the 75% percentile of the distribution in controls as the splitting threshold and used this binary variable in the logistic regression with breast cancer as the outcome.
In addition to the association between the two phenotypes, we analyzed a potential interaction/coincidence between them using a reversed regression model 9 with the two phenotypes as independent variables and the genotype as the dependent variable.
We report two-sided asymptotic 95% confidence intervals and p values. In the detection cohort in Level 1, we used Bonferroni correction (17 variants overall and 3 3 17 tests 
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after age stratification). In the verification cohort, only a single marker (rs3810813) was tested. In Level 2, the haplotypes of the genotyped variants were computed and tested for association using PLINK 1.07 which performs a 1 2 df v 2 test. Adjusted empirical p values were obtained for associations based on haplotypes using the permutation-based maxTmethod implemented in PLINK 1.9, thereby adjusting for the number of variants in the respective analysis. A credibility threshold for single marker association was determined by Bonferroni correction on the number of "independent" variants (N 5 54) remaining after pruning those of the 342 usable variants with a pairwise R 2 > 0.5 resulting in a threshold of p < 1 3 E-3.
Manhattan plots were generated using a custom R script from the p values obtained with PLINK1.9.
Results
An overview of the study is presented in Supporting Information, Figure S1 . Some details of the selected genes and variants are presented in Supporting Information, Table S2 .
A candidate variant in SLX4 (rs3810813) is associated with BC
The selected variants were first tested for an association with breast cancer in the detection cohort of 435 breast cancer cases and 1189 controls (Supporting Information, Table S1 ). One variant in the SLX4 gene, rs3810813, reached nominal significance with an odds ratio (OR) of 1.6 (95%CI 1.2-2.2, p 5 0.007); however, the association did not withstand Bonferroni correction for multiple testing of 17 variants (p 5 0.068, Supporting Information, Table S3 ). The minor allele frequency in controls (0.048) was almost identical to those reported for the central European population in publicly available datasets, including HapMap 15 (MAF 5 0.044), the Exome Aggregation Consortium (ExAC) 21 (MAF 5 0.052), and the 1000 genomes project 17 (MAF 5 0.05), while it varies within the lowfrequency range (0.01-0.18) in other populations (Supporting Information, Fig. S2 ). The BC association was substantially stronger when considering only cases with age of onset 60 years (OR 5 2.3 (95%CI 1.5-3.5), p 5 4.9 3 10
25
) and even more in those cases diagnosed 40 years (OR 5 4.3 (1.9-9.7), p 5 7.6 3 10 25 ) (Table 1A) , remaining significant after Bonferroni correction for 17 variants in the three age groups (51 tests, p 5 0.0025 and p 5 0.0036, respectively). Notably, among the BC cases with early onset 40 years, eight out of 23 cases (34%) carried the rs3810813 minor allele.
rs3810813 was subsequently genotyped in a verification cohort comprising 1404 controls and 1013 cases. The MAF in controls (0.053) was similar to that in the detection cohort. However the minor allele was not significantly increased among all BC cases or those with an age of onset 60 years in the verification cohort (Supporting Information, Table S3 ). In contrast, the association of the minor rs3810813 allele to BC in early onset cases 40 years of age could be confirmed (OR 5 1.82 (1.09-3.0), p 5 0.02). A combined analysis including the respective cohorts as covariate (Supporting Information, Table S3 ) revealed a clear association of the minor rs3810813 allele to BC overall and in cases with onset 60 years, and a markedly pronounced association in young-onset cases (OR 5 2.21(1.44-3.38), p 5 0.0003).
At this point, we considered the association to be real and validated. All further analyses were carried out to characterize the association and p values for all tagging SNVs (the haplotype) are reported to show that they behave similarly. The only additional phenotype (micronucleus frequency) studied was not assumed to be independent but to represent a functional intermediate to breast cancer.
The generally stronger associations seen in the detection cohort prompted us to study the only obvious difference between the cohorts that is constituted by the presence of a subgroup of 189 index cases from high-risk breast cancer families without BRCA1/2 mutation in the detection cohort. A separate analysis of familial and sporadic cases in this cohort (Supporting Information, Table S4 , A and B) demonstrated that the association of the tagging SNVs to BC was clearly present in both groups and depended on age of onset, with the highest statistical evidence among the familial cases diagnosed 60 years of age (best tagging SNV: OR 2.6 (1.6-4.2), p 5 2.3 3 10
). Among the sporadic cases of the detection cohort, age dependency was almost identical to that seen in the verification cohort. So, the association of rs3810813 with BC was established in our detection sample and confirmed in an independent cohort. It was much stronger in cases with early diagnosis (60 years) and may be more pronounced in familial cases. As this association appeared to be almost confined to early onset breast cancer that observation may best explained assuming a risk variant with very high penetrance tagged by rs3810813.
rs3810813 tags a specific haplotype associated with early onset breast cancer
To further characterize the association of the rs3810813 risk locus with breast cancer we generated a backbone for imputation with HapMap data by genotyping eight additional variants in the detection cohort: four inside the coding region of SLX4 and two markers each at the 5 0 and the 3 0 end outside of the SLX4 locus, spanning 150 kb in total (Fig. 1) .
Imputation of HapMap variants (CEU population) across the 150 kb region revealed that all (n 5 31) successfully imputed variants were in strong linkage disequilibrium (LD) (D 0 >0.9) and uncovered a specific low-frequency haplotype ( Fig. 1) which spans nearly the entire genotyped region and that is tagged by the BC-associated minor allele of rs3810813. Using the solid spline approach implemented in Haploview, 14 the region could be subdivided in six adjacent LD blocks, revealing that associations between BC and haplotypes were present in haplotypes of blocks 3, 4, and 5 ( Fig. 1 and Supporting Information, Table S5), with similar ORs (1.65) and significance (0.0019 < p < 0.0043). These associations p values up to rs118161359 as a consequence of the high LD in the region. As the risk alleles had no effect on MN frequency (Fig. 4) the Table reports results from cases only. In controls only, we observed beta 
Cancer Genetics and Epigenetics
were stronger when restricting cases to younger age of onset for all three associated blocks (ORs 2.33-2.59 in cases 60 and ORs 4.17-4.36 in cases 40 (Supporting Information, Table S5 )). None of the imputed HapMap variants alone was significantly associated to BC. However, a second round of imputation using the 1000 genomes data 17 (http://www. internationalgenome.org) yielded four further variants, that showed a strong association to BC (Table 1A) . They are distributed throughout the analyzed region (Fig. 2) Fig. S3 ). Each of the associated haplotype blocks from imputation against HapMap was tagged by at least one of the markers (Fig. 2) , but a haplotype generated from a combination of these variants did not improve the association further. However, the high R 2 (Supporting Information, Table S6) between the tagging markers precluded any conclusion on the location of a potential causal variant. Thus, we have established an association between a specific haplotype in the SLX4 region and breast cancer with early onset of the disease ( Figs. 1 and 2 ). This haplotype appeared to be specific for the population of Central Europe, absent from Africa and considerably rearranged in Asian populations (Supporting Information, Fig. S2 ).
Association of the specific haplotype with DNA doublestrand break repair capacity
The second phenotype in this study, DNA repair capacity as measured by the MNT, revealed similar associations to the same variants that were associated with BC, although with weaker significance. SLX4 had been selected as a candidate gene for this study as it is, like most well-established BC risk genes, involved in the repair or prevention of DNA double (Table 2 ) was used as index variant in all plots (a-f), and is shown in purple. Pairwise R2 between other variants and the index variant is color coded (blue, low R2, orange, red: high R2) through all plots. The blue horizontal line indicates nominal significance, the red line corresponds to Bonferroni correction for the number of independent (R 2 < 0.5) variants. The rows of variants with identical p values reflect series of variants with (mostly) a protective effect and similar MAFs. As can be seen in most plots, the high R 2 throughout the region decays around rs3794700 in the DNASE1 gene. Note the similarity of association patterns between breast cancer (a-c) and the micronucleus test (d-f) and its persistence also in those age strata in which significance drops. The only exception is the MN frequency without stratification (d) where a different variant, rs12929402 attains credible significance. This signal is clearly independent from the risk haplotype ( Supporting Information, Fig. S2 ) concerning R 2 disappears with age stratification and is located centromerically where R 2 decays.
strand breaks. We studied if the presence of the specific haplotype that is associated with BC risk also manifests in the DNA repair phenotype. The presence of micronuclei (MN) after induction of DNA double strand breaks, was studied as a second (intermediate) phenotype in a subset of samples from the detection cohort. While the MN frequency was only marginally increased when BC cases were compared to controls overall (Fig. 4a) , a separation according to the rs3180813 genotype revealed an increase in MN frequency confined to BC cases carrying the specific haplotype (Figs. 4b-d).
In line with these descriptive observations, the specific haplotype revealed a very modest association with MN frequency considering all cases and controls (beta 8.7 (0.49-15.9), p 5 0.038). As expected, this association is strongly influenced by the case or control status, an observation supported also by the significant interaction between status and variant genotypes in the linear model (p 5 0.024). No association was present when only controls were considered (p 5 0.85). Using only BC cases, the associations between the tagging variants and MN frequency increased the beta values considerably (Table 2B ). The age effect seen in the breast cancer association was also detected for MN-frequency. Analyzing cases with early onset (60 years or 40 years, respectively) showed a more pronounced association of the specific haplotype with DNA repair capacity (up to beta 5 37.8 (17.9-57.7); p 5 5.3 3 10 24 in cases 60 years) (Table 1B and  Figs. 3d-f), in spite of the small remaining number of cases.
Interestingly, when considering all BC cases, MN frequencies were additionally associated with several variants centromeric of the risk haplotype, most significantly to rs12929402. However, this association was not present in any other stratum ( Fig. 2 and Supporting Information, Fig. S3 ), the variants are not associated to breast cancer (Fig. 2a-c) , and they are not in LD with the risk haplotype (Supporting Information, Table S6 ). This accessory finding needs to be independently explored.
Congruence of associations of the two phenotypes with the specific haplotype
The observation that both phenotypes were associated with largely the same set of variants is apparent from the Manhattan plots (Fig. 2, comparing a-c to d-f) . It is further corroborated by the similar age dependence of both phenotypes and the significant interaction between case or control status and MN frequency. We jointly analyzed the associations of the two phenotypes with the tagging variant genotypes using the standard reversed regression model approach. 9 This confirmed the associations for BC (p < 0.0001), MN frequencies (p 5 0.0055), and the interaction term (p 5 0.015). The result for rejection of the global H 0 was also significant (p 5 0.0014).
In our study, however, most of the relevant information for the interpretation of the associations came from age stratification and from analysis of LD structure of the region after imputation. Receiver-operating characteristic (ROC) curves were calculated and the area under the curve (AUC) is reported. To generate OR values in addition, the MN frequencies were classified as low or high (dichotomized) using the 75% percentile of the controls as cutoff and the OR with its p values was calculated by logistic regression. The number of cases and controls for "dichotomized" are higher as age or genotype information was not available for all MNT results.
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Who carries the risk variant?
One possibility to explain the age specific distribution of OR and p values in Table 1A was the assumption that only a proportion of the specific haplotypes carried the causal risk variant. Therefore, we tested if there is any association of the specific haplotype with BC in late (60 years) onset cases and did not find anything (best marker rs58832719, p 5 0.19, OR 5 1.3, N cases 5 275, N control 5 1189) while cases with onset 40 years retained some of the risk (rs58832719, p 5 0.013, OR 5 1.5, N cases 5 415, N control 5 1189), probably in the cohort with disease onset 40-60 years. Furthermore, a corresponding observation was made with MN frequency, where carriers of the specific haplotype reveal a detectable effect only when they are affected by BC (Table 1B) but not in controls (beta 5 0.85 (27.2-8.9), p 5 0.83). The association with MN frequency in cases only exhibits the same dependency on age of onset as the association with BC. Both observations, concerning BC and MN frequency, may best be explained by a variant with very high penetrance present only on a subgroup of the specific haplotype ( Supporting  Information, Fig. S5 ).
Breast cancer is associated with micronucleus frequency
We found a significant association of the MN frequency with breast cancer overall (p 5 0.008, 268 controls and 134 breast cancer cases) and also in those individuals with available age information (268 controls, 98 cases) ( Table 2 and Fig. 4 ). As expected from the correlation of MN frequency and the risk haplotype, this association was present only in the carriers of the specific haplotype (p 5 0.0001) but not in carriers of the wild-type genotype (p 5 0.7) (Fig. 3b) . Concordantly, the association between breast cancer and MN frequency was again more pronounced in BC patients with younger age (60 years: OR 5 3.58 (2.07-6.18), p < 0.0001) (Figs. 3c and 3d and Table 2 ). ROC curves for the prediction of BC risk by induced micronucleus frequencies revealed an increasing area under the curve (AUC 5 0.59 up to 0.69) in younger individuals (Figs. 4a-c) . Restricting the ROC analysis to carriers of the specific haplotype (Fig. 4d) yielded AUCs of 0.88 up to 0.96 (CI 0.72-1.0) in the three age groups (Table 2) . Notably, patients diagnosed before age 60 who carry the risk haplotype can be attributed to the risk group with high accuracy using their MN frequency (Fig. 4d) . These observations agree well with the idea that the hypothetical causal variant impairs DNA repair and that this impairment may be the cause of the BC risk.
Discussion
We have identified an association of a specific haplotype spanning NLRC3, SLX4/FANCP, DNASE1, and TRAP1 with early onset breast cancer risk in a case/control study and confirmed this association for a tagging variant (rs3810813) in an independent verification sample. The same haplotype is associated additionally with micronucleus (MN) frequency, a functional measure of DNA repair capacity. The association with increased MN frequency was observed only in BC patients, indicating that the causal variant is present only in this subgroup of the risk haplotype carriers. The associations of the risk haplotype to both phenotypes exhibited a strong and identical dependency on the age of onset of breast cancer. MN frequency and breast cancer were also associated with each other, again depending on age of BC onset. This age effect is compatible with the assumption that a subgroup of the risk haplotypes confers a very high risk for early onset disease whereas the remainder of the specific haplotypes does not. Furthermore, the lack of BC association in cases diagnosed >60 years and the absence of an effect of the specific haplotype on MN frequency in controls may indicate that the specific haplotype does not carry the causal variant in these groups. This idea would agree well with an almost complete penetrance of the causal variant which would shift all carriers of the causal variant into the patients cohort and, due to early disease onset, prevent their appenrence among patients diagnosed at >60 years. A candidate gene for the observed associations should explain breast cancer susceptibility and, at the same time, an impairment of DNA repair capacity. The specific haplotype covers four genes (UCSC genome browser; http://genome. ucsc.edu/). 22 At the centromeric end of the haplotype, the linkage disequilibrium starts to decay at rs3794700 (Supporting Information, Fig. S3 ), which is located in an intron of TRAP1. This gene encodes a mitochondrial HSP90 protein which associates with Ext1, 23 interacts with Rb1 24 and may be involved in tumorigenesis. 25 There is currently no indication of an involvement in DNA repair. DNASE1 appears to be relevant for the elimination of free DNA from peripheral blood and thus influences some autoimmune diseases. DNASE1 mutations (OMIM 25505; http://www.ncbi.nlm.nih. gov/omim) have been found in patients with systemic lupus erythematosus (SLE, OMIM 152700) 26 and a coding variant was associated with SLE. 27 However, functions in DNA repair are not reported for this gene. At the telomeric end of the haplotype, the most distal tagging variant is located in an intron of NLRC3. This gene belongs to the innate immune system and has regulatory function in the NF kappa B pathway. 28 Using a knock out mouse model, NLRC3 has recently been shown to play a key role in colon tumorigenesis and to be essential in regulating the PI3K-mTOR pathway, 29 but a direct connection to DNA repair is neither reported nor likely. In contrast to these three genes, SLX4 has been identified as a causative gene for Fanconi Anemia (complementation group P, FANCP), 30, 31 a DNA repair defect syndrome with autosomal recessive inheritance. SLX4 fulfills a multitude of functions in a variety of DNA repair pathways including repair of DNA interstrand cross-links, doublestrand breaks, and the resolution of Holliday junctions. 12, 32 Moreover, SLX4 defective cells exhibit chromosomal instability, manifesting among others an increased numbers of micronuclei 33 -reminiscent of the increased MN frequencies that we observed here to be associated with the specific haplotype. SLX4 fulfills both conditions for a candidate gene to explain both associations and is clearly the best candidate among the four genes located in the region of the specific haplotype.
Owing to the stability and extent of the haplotype, it is not possible to formally decide where in the haplotype the 
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risk variant is located. The initially investigated variant, rs3810813, does not qualify as the causal variant for the observed phenotypes, despite the classification of the resulting amino acid exchange Ser1271Phe as probably damaging (Grantham score 155, PolyPhen score 0.97). The frequency of homozygotes corresponds to the expectation from HWE observed in our study (n 5 8), in the ExAC database, and in the 1000 genomes data, and homozygous carriers of a deleterious mutation would be expected to be affected by Fanconi anemia. The same reasoning applies to the other variants of the risk haplotype.
Considering the multiple functional domains of SLX4, one might be tempted to speculate that the causal variant is a dominant negative mutation which abolishes one of the functions of this gene. A dominant negative mutation is here suggested as an example explaining a monoallelic effect as seen in the micronucleus test. However, other models, like interaction of the hypothesized causal variant with an SNV in another gene are possible as well. The dominant negative variant might be lethal in a homozygous state. The MAF of rs 3810813 would be considerably higher than that of the causal variant and a lethal effect of a homozygous causal variant would hardly be detectable in HWE of the tagging variant rs3810813.
A dominant negative mutation has not been observed in the >2500 index cases from hereditary breast cancer families which have been analyzed for deleterious mutations in the coding sequences of the SLX4 gene in eight studies. [34] [35] [36] [37] [38] [39] [40] [41] In one of these studies, the LD structure of the region was detected and two selected variants were tested for association in larger cohorts. This resulted in a borderline association of rs138615800 (p 5 0.05, OR 5 4.27) 40 in patients diagnosed <40 age of years similar to our results. However, the minor allele of the other marker did not tag the specific haplotype described here and the minor allele of rs138615800 was absent (not imputed) from our dataset. The frequency of monoallelic deleterious mutations (loss of function) observed by Sanger sequencing at 1:875 does not exceed the frequency of LOF mutations reported by ExAC. In the present study, the frequency of risk allele carriers among early onset cases diagnosed at 40 years was about 25% (8/23 in the detection cohort and 28/110 in the combined cohorts). Generalizing this finding by taking into account that, as these early affected cases represent 2.7% of the overall breast cancer incidence (as determined from SEERS data 2000-2009; http://seer.cancer.gov/), the contribution of the risk allele to overall breast cancer incidence would be estimated to be in the order of up to 1:150 breast cancer patients. In consequence, the BC risk observed in our association study is difficult to explain by deleterious mutations in the coding sequence of SLX4 because these mutations are too rare. Of course, these numbers constitute only rough estimates and we have to await more detailed studies before conclusions can be drawn.
Many of the susceptibility genes for breast cancer are involved in the removal of DNA interstrand cross-links and repair of double strand breaks and several are constituents of the Fanconi anemia DNA repair pathway. Heterozygous deleterious mutations in these genes have been assumed to manifest in a reduced DNA repair capacity, which has been demonstrated repeatedly (for example 42, 43 and in two instances (BRCA1 44 and ATM 45 ) with the MN test. The association between MN frequencies with or without mutagenic challenge and breast cancer in general has been frequently addressed in studies searching for biomarkers of breast cancer risk. 46, 47 The results were, however, conflicting, [48] [49] [50] and a recent meta-analysis concluded that the evidence for an association between altered MN frequencies and cancer risk is not yet sufficient to use the MNT in clinical testing. 10, 51 In our data, we observed a strong association of reduced DNA repair capacity with the presence of the specific haplotype, particularly in early onset BC cases. Furthermore, the dependence on age and genotype demonstrates the inherent causal relationship between all three associations. In addition to the detection of heterozygotes of ATM and BRCA1 mutations by the MNT, 44, 45 our data provide one of the few examples of a strong correlation between a genotype and induced MN frequency and thus support the relevance of induced MN frequencies in the context of breast cancer research. The additional use of induced MN frequency on cases carrying the risk haplotype allows to identify those who carry the suspected "causal variant" with high accuracy (AUC >0.9) among the BC cases with an age of onset 60 years and may thus help to identify the causal variant.
Limitations of this study
This study is not complemented by sequencing data. We could not obtain funding to sequence the complete haplotype region in a sensible manner (WGS or custom enrichment of the whole very large region) in a large enough sample size that would lead to further insights beyond the characterization of the here identified tagging SNVs. As no further sample material could be obtained from any of our cohorts, we could not perform additional characterization via RNASequencing. Recently, this approach was shown to be able to uncover pathogenic sequence variations that are usually missed via DNA approaches, either by highlighting variants that were previously not thought to be pathogenic, or identifying causative variants located deeply in non-coding regions. 52 We plan to address these issues in a future study.
Conclusions
Starting from a candidate gene approach in a case/control study for breast cancer and DNA repair capacity, we found associations to a specific, low-frequency haplotype in a 150 kb region containing the SLX4 gene. Both associations are characterized by (i) a strong dependency on age of onset of breast cancer, being almost absent from cases >60 years and highly enriched in cases 40 years; (ii) the risk appears to be present only on a subset of those cases carrying the specific haplotype; (iii) both phenotypes are associated also with each other and can be used together to identify the carriers of the causal variant among the carriers of the specific haplotype in early onset BC cases. (iv) The observations reported here can fully be explained by assuming a yet-unknown causal variant with very high penetrance for early onset disease on a subset of the specific haplotype. This assumption would predict the absence of the causal variant from controls (leaving the specific haplotype without effect on MN frequency in controls, as observed here) and their disappearance from cases diagnosed >60 years. In spite of the validation of the association between rs3810813 and BC in an independent cohort, the study has to be expanded to other populations than the Central European and the age distribution, and familial occurrence of the risk need to be assessed in more detailed studies.
